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CHAPTER 1 - Introduction 
EŝƚƌŝĐKǆŝĚĞŝƐĂĨƌĞĞƌĂĚŝĐĂůƚŚĂƚŚĂƐŵĂŶǇŝŵƉŽƌƚĂŶƚĂŶĚĚŝǀĞƌƐĞďŝŽůŽŐŝĐĂůƌŽůĞƐƐƵĐŚ
ĂƐ Ă ĐĞůů ƐŝŐŶĂůůŝŶŐ ŝŶĐůƵĚŝŶŐ ĞůĞǀĂƚŝŽŶ ŽĨ Đ'DW ůĞǀĞůƐ  ?ǀŝĂ ŝŶŚŝďŝƚŝŽŶ ŽĨ ŐƵĂŶǇůĂƚĞ
ĐǇĐůĂƐĞ )ǁŚŝĐŚƉůĂǇƐĂŶŝŵƉŽƌƚĂŶƚƌŽůĞŝŶƐŵŽŽƚŚŵƵƐĐůĞƌĞůĂǆĂƚŝŽŶĂŶĚǀĂƐŽĚŝůĂƚŝŽŶ
 ? ? ? ? ? ?  ,ŽǁĞǀĞƌ ? EK ĂůƐŽƉůĂǇƐ Ă ŵĂũŽƌ ƌŽůĞ ŝŶ ƚŚĞ ŝŵŵƵŶĞ ƐǇƐƚĞŵ ŝŶ ƚŚĞĚĞĨĞŶĐĞ
ĂŐĂŝŶƐƚ ŝŶǀĂĚŝŶŐďĂĐƚĞƌŝĂ ?dŚĞƌĞĂƌĞĂǀĂƌŝĞƚǇŽĨĐĞůůƵůĂƌƚĂƌŐĞƚƐĨŽƌEKŝŶďĂĐƚĞƌŝĂ ?
ĂŶĚ ŵŽƐƚ ƉĂƚŚŽŐĞŶŝĐ ďĂĐƚĞƌŝĂ ĚŝƐƉůĂǇ Ă ƌĞƐƉŽŶƐĞ ƚŽ ƚŚŝƐ ŶŝƚƌŽƐĂƚŝǀĞ ƐƚƌĞƐƐ ? ǁŚŝĐŚ
ƌĞƐƵůƚƐŝŶƚŚĞĐŝƌĐƵŵǀĞŶƚŝŽŶŽĨƚŚĞƚŽǆŝĐĞĨĨĞĐƚƐŽĨEKĂŶĚŝƚ ?ƐĚŽǁŶƐƚƌĞĂŵƉƌŽĚƵĐƚƐ
ƌĞĨĞƌƌĞĚ ƚŽ ĂƐ ƌĞĂĐƚŝǀĞ ŶŝƚƌŽŐĞŶ ƐƉĞĐŝĞƐ  ?ZE^ ) ? dŚŝƐƐƚƵĚǇ ĨŽĐƵƐƐĞƐ ŽŶ ƚŚĞ ĞŶƚĞƌŝĐ
ƉĂƚŚŽŐĞŶ ?ũĞũƵŶŝĂŶĚƚŚĞƚƌĂŶƐĐƌŝƉƚŝŽŶĂůƌĞŐƵůĂƚŽƌEƐƐZ ?EŝƚƌŽƐĂƚŝǀĞƐƚƌĞƐƐƐĞŶƐŝŶŐ
ZĞŐƵůĂƚŽƌ )ƚŚĂƚĐŽŶƚƌŽůƐƚŚĞŵĂũŽƌƌĞƐƉŽŶƐĞƚŽEK ? 
 
1.1 Nitric oxide and nitrosative stress in bacteria 
Nitric oxide (NO) is a free radical that readily reacts with a wide variety of biological 
molecules. As a result there are a complex array of reactive nitrogen species (RNS).  
NO has many diverse and important biological functions in the human body such as 
playing a major role in the immune system in the defence against pathogen bacteria 
by damaging bacteria through nitrosative stress.  This can occur directly from NO but 
also from other RNS that are formed by NO (e.g. nitrosonium ion NO+, peroxynitrite 
ONOO-).  EKŝƐŐĞŶĞƌĂƚĞĚďǇŵĂĐƌŽƉŚĂŐĞƐ ?ŵŽŶŽĐǇƚĞƐĂŶĚŶĞƵƚƌŽƉŚŝůƐǀŝĂƚŚĞĂĐƚŝŽŶ
ŽĨŝŶĚƵĐŝďůĞŶŝƚƌŝĐŽǆŝĚĞƐǇŶƚŚĂƐĞƐ ?ǁŚŝĐŚŝƐŝŶĚƵĐĞĚďǇďĂĐƚĞƌŝĂů>W^ ? ? ?ĂŶĚĐŽŶǀĞƌƚƐ
> ?ĂƌŐŝŶŝŶĞ ŝŶƚŽ ĐŝƚƌƵůůŝŶĞ ĂŶĚ EK ?  EK ŝƐhighly lipophilic and can cross of the cell 
membrane of bacteria, and ƚŚĞƌĞĂƌĞŵĂŶǇĐĞůůƵůĂƌƚĂƌŐĞƚƐĨŽƌZE^ ?&ŽƌĞǆĂŵƉůĞ ?EK
ĐĂŶĐĂƵƐĞEĚĂŵĂŐĞĂŶĚĐĂŶŝŶŚŝďŝƚEƌĞƉĂŝƌĂŶĚƐǇŶƚŚĞƐŝƐ ? ? ? ?EKƐƚƌĞƐƐĐĂŶ
ĂůƐŽĐĂƵƐĞĚĂŵĂŐĞ ƚŽƉƌŽƚĞŝŶƐǀŝĂ ^ ?ŶŝƚƌŽƐǇůĂƚŝŽŶ ? ? ? ? ƚǇƌŽƐŝŶĞ ŶŝƚƌĂƚŝŽŶ ? ? ?ŽƌW
ƌŝďŽƐǇůĂƚŝŽŶ ? ? ? ?EKĂůƐŽŚĂƐďƌŽĂĚ ?ĂĐƚŝŶŐƚŽǆŝĐŝƚǇďǇďŝŶĚŝŶŐƚŽŚĂĞŵŐƌŽƵƉƐ ?&Ğ ?^
ĐůƵƐƚĞƌƐĂŶĚǌŝŶĐĨŝŶŐĞƌƐ ? ? ? ? ? ? 
 
As well as being a signal NO has a potent antimicrobial effect, in the presence of 
dioxygen or superoxide NO can be further oxidised to nitrite (NO2-) or peroxynitrite 
(ONOO-) which are strong oxidising agents which can damage DNA, protein and cell 
walls.  Interestingly, some bacteria are known to have their own nitric oxide synthase 
11 
 
enzymes and purposefully synthesise their own NO when in their host.  This is due to 
NO being a known modulator of proteins for instance some bacteria have proteins 
that when S-nitrosylation of specific cysteine thiols occur specific genes related to 
NO tolerance and the detoxification of NO are upregulated [10]. Also, it has been 
reported that NO can diminish the efficacy of certain antibiotics [11], which could 
provide a growth advantage to NO-producing bacteria if their environmental niche is 
shared by antibiotic-producing bacteria or fungi.  
 
1.2 - Campylobacter jejuni and disease 
 ?ũĞũƵŶŝ ƐĂŵŽƚŝůĞŵŝĐƌŽĂĞƌŽƉŚŝůŝĐǌŽŽŶŽƚŝĐ'ƌĂŵ ?ŶĞŐĂƚŝǀĞďĂĐƚĞƌŝƵŵǁŝƚŚĐƵƌǀĞĚ
ďĂĐŝůůŝŵŽƌƉŚŽůŽŐǇ ?ƐĂŶĞŶƚĞƌŝĐƉĂƚŚŽŐĞŶ ? ?ũĞũƵŶŝ ƐŽĨƚĞŶĨŽƵŶĚŝŶĨĂĞĐĞƐ ?/ƚŚĂƐ
ĐůŝŶŝĐĂůŝŵƉŽƌƚĂŶĐĞŝŶƚŚĞƉĂƚŚŽůŽŐǇŽĨŐĂƐƚƌŽĞŶƚĞƌŝƚŝƐĂŶĚŝƐŽŶĞŽĨƚŚĞŵŽƐƚĐŽŵŵŽŶ
ĐĂƵƐĞƐǁŽƌůĚǁŝĚĞ ?ƌŽƵŶĚ ? ?A?ŽĨƉĂƚŝĞŶƚƐĂƌĞĐŽŶƐŝĚĞƌĞĚĂƐǇŵƉƚŽŵĂƚŝĐǁŚŝĐŚŵĂǇ
ŝŶĐƌĞĂƐĞ ƚŚĞ ƐƉƌĞĂĚ ŽĨ ƚŚĞ ƉĂƚŚŽŐĞŶ ĞƐƉĞĐŝĂůůǇ ŝŶ ƵŶƐĂŶŝƚĂƌǇ ĐŽŶĚŝƚŝŽŶƐ ?
'ĂƐƚƌŽĞŶƚĞƌŝƚŝƐŝƐĐŚĂƌĂĐƚĞƌŝƐĞĚďǇĐƌŝƉƉůŝŶŐĂďĚŽŵŝŶĂůĐƌĂŵƉƐ ?ĚŝĂƌƌŚŽĞĂĂŶĚĨĞǀĞƌ
ŚŽǁĞǀĞƌŵŽƐƚĐĂƐĞƐĂƌĞƵƐƵĂůůǇƌĞƐŽůǀĞĚŝŶƵŶĚĞƌĂǁĞĞŬǁŝƚŚŽƵƚƚŚĞƚƌĞĂƚŵĞŶƚǁŝƚŚ
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1.3 - Bacterial NO-sensing transcription factors 
dŚĞƌĞĂƌĞƐĞǀĞƌĂůďĂĐƚĞƌŝĂůƚƌĂŶƐĐƌŝƉƚŝŽŶƌĞŐƵůĂƚŽƌƐƚŚĂƚƐĞŶƐĞEK ?ƚŚĞƐĞƐĞŶƐĞEK
ƵƐŝŶŐǀĂƌŝŽƵƐŵŽůĞĐƵůĂƌŵĞĐŚĂŶŝƐŵƐ ?dŚĞƐĞĐĂŶƚŚĞŶƵƉƌĞŐƵůĂƚĞĞǆƉƌĞƐƐŝŽŶŐĞŶĞƐ
ŝŶǀŽůǀĞĚ ŝŶ EK ĚĞƚŽǆŝĨŝĐĂƚŝŽŶ  ? ? ? ? ?   dŚŝƐ ƉƌĞǀĞŶƚƐ ďƵŝůĚ ?ƵƉ ŽĨ EK ƚŽ ƚŽǆŝĐ
ĐŽŶĐĞŶƚƌĂƚŝŽŶƐĂŶĚĐĂŶĂůƐŽƵƉ ?ƌĞŐƵůĂƚĞŐĞŶĞƐŝŶǀŽůǀĞĚŝŶEƌĞƉĂŝƌĨƌŽŵĚĂŵĂŐĞ
ƚŚĂƚŚĂƐĂůƌĞĂĚǇŽĐĐƵƌƌĞĚ ? ? ? ? ĂĐƚĞƌŝĂůEK ?ƐĞŶƐŝŶŐƚƌĂŶƐĐƌŝƉƚŝŽŶĨĂĐƚŽƌƐĂƌĞĚŝǀŝĚĞĚ
ŝŶƚŽ ?ŵĂŝŶŐƌŽƵƉƐ ?ƚŚŽƐĞǁŝƚŚĂƉƌŝŵĂƌǇƌŽůĞŝŶEKƐĞŶƐŝŶŐƐƵĐŚĂƐWƐĞƵĚŽŵŽŶĂƐ
ĂĞƌƵŐŝŶŽƐĂ EZ  ǁŚŝĐŚ ƐĞŶƐĞƐ EK ǀŝĂ Ă ƉƌŽƐƚŚĞƚŝĐ ŚĂĞŵ ŐƌŽƵƉ ? ĂŶĚ ƚŚŽƐĞ ǁŝƚŚ
ƐĞĐŽŶĚĂƌǇƌŽůĞƐƵĐŚĂƐ&EZŝŶ ?ĐŽůŝ ? ? ? W ? ? ? P&EZƐĞŶƐĞƐEKǁŝƚŚĂŶŝƌŽŶ ?ƐƵůƉŚƵƌ 
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ĨůĂǀŽŚĂĞŵŽŐůŽďŝŶ ,ŵƉ ĞŶǌǇŵĞ ǁŚŝĐŚ ŝƐ Ă ĐŽŵŵŽŶ EK ĚĞƚŽǆŝĨǇŝŶŐ ĞŶǌǇŵĞ ƚŚĂƚ
ĚĞƚŽǆŝĨŝĞƐ EK ƚŽ ŶŝƚƌĂƚĞ Žƌ ŶŝƚƌŽƵƐ ŽǆŝĚĞ ǀŝĂ ǁĞůů ?ĐŚĂƌĂĐƚĞƌŝƐĞĚ ŵĞĐŚĂŶŝƐŵƐ ďŽƚŚ
ƵŶĚĞƌĂĞƌŽďŝĐĂŶĚĂŶĂĞƌŽďŝĐĐŽŶĚŝƚŝŽŶ ? ? ? ?  
 
Figure 1.1  ? Structures of Hmp of E.coli.  Crystal structural model of NO detoxification 
enzyme Hmp with reduction domains highlighted, b-type haem cofactor (green) and bound 




1.4  W The NssR regulon of C.jejuni 
ĂŵƉǇůŽďĂĐƚĞƌũĞũƵŶŝůĂĐŬƚŚĞŵĂũŽƌŝƚǇŽĨEKƐĞŶƐŝŶŐĂŶĚĚĞƚŽǆŝĨŝĐĂƚŝŽŶƐǇƐƚĞŵƐŝŶ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 ? ? ? ? ? dŚŝƐ ƌĞŐƵůŽŶ ŝŶĐƵĚĞƐ ŐĞŶĞƐ ĞŶĐŽĚŝŶŐ ƚǁŽ ŐůŽďŝŶ ƉƌŽƚĞŝŶƐ ? Őď ĂŶĚ ƚď  ?Őď
ƐŝŶŐůĞĚŽŵĂŝŶŐůŽďŝŶ ?ƚďƚƌƵŶĐĂƚĞĚŐůŽďŝŶ ) ?ŐďŝƐƚŚŽƵŐŚƚƚŽĚĞƚŽǆŝĨǇEKĚŝƌĞĐƚůǇ ?
ǁŚĞƌĞĂƐƚŚĞƌŽůĞŽĨƚďŝƐŵŽƌĞƉŽŽƌůǇƵŶĚĞƌƐƚŽŽĚĂŶĚŚĂƐďĞĞŶŝŵƉůŝĐĂƚĞĚŝŶŽǆǇŐĞŶ
ŵĞƚĂďŽůŝƐŵ  ? ? ? ? ? ? ? ? dŚĞ ŝŶƚĞƌƉůĂǇ ďĞƚǁĞĞŶ EƐƐZ ?ŵĞĚŝĂƚĞĚ EK ƐĞŶƐŝŶŐ ĂŶĚ Őď ?
ŵĞĚŝĂƚĞĚEKĚĞƚŽǆŝĨŝĐĂƚŝŽŶŝƐƐŚŽǁŶŝŶ&ŝŐƵƌĞ ? ? ?EKŝƐŝŶĚŝƌĞĐƚůǇƐĞŶƐĞĚďǇEƐƐZ
ǁŚŝĐŚůĞĂĚƐƚŽƵƉ ?ƌĞŐƵůĂƚŝŽŶŽĨŐďĞǆƉƌĞƐƐŝŽŶůĞĂĚŝŶŐƚŽĚĞƚŽǆŝĨŝĐĂƚŝŽŶŽĨEK ? 
 
 
Figure 1.2 - Simplified model of mechanism of NO sensing and detoxification in C. jejuni by 
the NssR detoxificstion system.  NssR activity is positively regulated indirectly by NO.  The 
increased activity of NssR positively modulates Cgb expression leading to the NO 
detoxification to nitrate.  adapted from Monk  et al(2008)[26]. 
 
EƐƐZŝƐĚŝƐƚŝŶĐƚĨƌŽŵEƐƌZŽĨ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ĞŶŝƚƌŽƐǇůĂƐĞƌĞĂĐƚŝŽŶ ܥܾ݃ െ ܨ݁ሺܫܫሻ ൅ ܱܰ ? ՞ ܥܾ݃ െܨ݁ሺܫܫሻܱܰ ൅ ܱଶ  ՜ ܥܾ݃ െ ܨ݁ሺܫܫܫሻ ൅ ܱܰଷି  
 
tŚŝĐŚ ƌĞĂĐƚŝŽŶ ƉƌĞĚŽŵŝŶĂƚĞƐ ĚƵƌŝŶŐ ŝŶĨĞĐƚŝŽŶ ŝƐ ĐŽŶƚĞŶƚŝŽƵƐ ? /ƚ ŝƐ ƉƌĞĚŝĐƚĞĚ ƚŚĂƚ
ĚƵƌŝŶŐ ƚŚĞ ŝŶŝƚŝĂů ƉŚĂƐĞ ŽĨ ŝŶĨĞĐƚŝŽŶ ƚŚĂƚ ƚŚĞƌĞ ŝƐ ĞŶŽƵŐŚ K ? ƉƌĞƐĞŶƚ ƚŚĂƚ ƚŚĞ
ĚŝŽǆǇŐĞŶĂƐĞƌĞĂĐƚŝŽŶŝƐŵŽƌĞůŝŬĞůǇ ?ǁŚĞƌĞĂƐĚƵƌŝŶŐƚŚĞůĂƚĞƐƚĂŐĞƐŽĨŝŶĨĞĐƚŝŽŶĂŶŽǆŝĐ
ĐŽŶĚŝƚŝŽŶƐĂŶĚĞůĞǀĂƚĞĚEKǁŽƵůĚĨĂǀŽƵƌƚŚĞĚĞŶŝƚƌŽƐǇůĂƐĞƌĞĂĐƚŝŽŶ ? ? ? ?  
ƚď ŝƐ Ă ƚƌƵŶĐĂƚĞĚ ŐůŽďŝŶ ƚŚĂƚ ĚŽĞƐ ŶŽƚ ĚŝƌĞĐƚůǇ ĚĞƚŽǆŝĨǇ EK ďƵƚ ŚĂƐ ďĞĞŶ
ŝŵƉůŝĐĂƚĞĚŝŶƌŽůĞƐƐƵƉƉŽƌƚŝŶŐƚŚŝƐǀŝĂŽǆǇŐĞŶŵĞƚĂďŽůŝƐŵĂŶĚĂůƐŽĚĞůŝǀĞƌǇŽĨŽǆǇŐĞŶ
ƚŽŐďƵŶĚĞƌŚǇƉŽǆŝĐĐŽŶĚŝƚŝŽŶƐ ? ? ? W ? ? ? More recently it has been proposed that 
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Ctb dampens the response to NO under hypoxic conditions, this would suggest that 






Figure 1.3  ? Structures of the globin proteins of C. jejuni.  )dŚĞ ‘ƚŚƌĞĞŽǀĞƌƚŚƌĞĞ ?ɲ-helical 
fold of Cgb (PDBid = 2WY4) with bound haem cofactor [29]  )dŚĞ ‘ƚǁŽŽǀĞƌƚǁŽ ?ɲ-helical 
fold of Ctb (PDBid = 2IG3) with bound haem cofactor [30] 
 
    
C. jejuni  is also known to possess a NrfA nitrite reductase, with homologues 
of this enzyme being found in a large range of bacteria [31,32].  The primary role of 
NrfA is in anaerobic respiration, but NrfA of C.jejuni has been shown to provide 
tolerance to NO independent of the NssR regulated detoxification system [23] 
However, mutation of cgb and nssR genes have been shown to cause severe growth 
inhibition in the presence of NO whereas mutation of nrfA had only resulted in 
slightly slowed growth.  This suggests that the NssR-regulated NO detoxification 
system plays a more important role in detoxification of NO  [31]. 




1.6 - Cyclic nucleotides as bacterial signals 
NssR has been shown to possess a cyclic nucleotide binding domain and contains 
sequence similarities to the helix turn helix DNA binding domain of the transcription 
factor Crp [33].  Proteins the have a cyclic nucleotide binding domain are likely to 
bind cAMP or cGMP and possess a common domain of around 120 amino acids 
composed of three alpha-helices and a distinctive eight-stranded, antiparallel beta-
barrel structure.  The archetypal Crp family member is the cAMP receptor protein 
Crp which is a known global regulator of genes largely involved in energy 
metabolism.  c-GMP is a well-characterised signal in eukaryotic cells and is an 
excellent signalling molecule having a much higher stability than cAMP.  However, in 
bacterial cells there is little evidence of its use as a signal.  Conversely, the dimerised 
form of c-GMP, c-di-GMP, has a well-characterised role in NO sensing in P. aeruginosa 
where phosphodiesterase and diguanylase cyclase enzymes, which control c-di-GMP 
levels, have previously been shown to be modulated by NO [34,35]. Hence, c-di-GMP 
is a strong candidate for being a second messenger in NO-mediated activation of 
NssR activity. It was therefore hypothesised that iŶĐƌĞĂƐĞĚ ůĞǀĞůƐŽĨĐ ?Ěŝ ?'DWǁŝůů
ĞůĞǀĂƚĞEƐƐZĂĐƚŝǀŝƚǇŝŶĐƌĞĂƐŝŶŐŐďĞǆƉƌĞƐƐŝŽŶ ?&ŝŐƵƌĞ ? ? ? ) ? 
 




1.7 Project aims 
dŚŝƐ ǁŽƌŬ ĂŝŵƐ ƚŽ ĐŽŶĨŝƌŵ EƐƐZ ĂƐ Ă ĐǇĐůŝĐ ŶƵĐůĞŽƚŝĚĞ ďŝŶĚŝŶŐ ƉƌŽƚĞŝŶ ƚŚƌŽƵŐŚ
ƐƚƌƵĐƚƵƌĂů ŵŽĚĞůůŝŶŐ ĂŶĚ ďŝŽĐŚĞŵŝĐĂů ?ƐƉĞĐƚƌŽƐĐŽƉŝĐ ďŝŶĚŝŶŐ ĞǆƉĞƌŝŵĞŶƚƐ ? &ƵƌƚŚĞƌ
ĂŝŵƐŝŶĐůƵĚĞŝĚĞŶƚŝĨŝĐĂƚŝŽŶŽĨƚŚĞĞǆĂĐƚŶƵĐůĞŽƚŝĚĞƚŚĂƚďŝŶĚƐƚŽEƐƐZŝŶǀŝǀŽ ?ĂŶĚƚŽ





CHAPTER 2 - MATERIALS AND METHODS 
 
2.1 Bacterial strains, plasmids, and growth conditions 
 
The bacterial strains and plasmids used in this work are listed in Table 2.1. 
  




E. coli TOP 10 - - Invitrogen 
E. coli TOP 10 pGEM-T-cgb promoter Ap Smith et al (2011) 
BL21 DE3 pGEX-KG-N-nssR Ap Smith et al (2011) 
E. coli TOP 10 pSB1C3-Prom/RBS Cm Shepherd lab 
E. coli TOP 10 pSB1C3-cgb promoter Cm This work 
E. coli MC1000  - - 
Spiro & Guest 
(1987) 
E. coli D ? ? ? ?ȴyfgF - Cm Lacey et al (2010) 
E. coli TOP10  pRS415-cgb promoter -lacZ Ap Shepherd lab  
E. coli TOP10  pSU2718-G-nssR Gm  Shepherd lab  
E. coli MC1000 pRS415 Ap  Shepherd lab  
E. coli MC1000  pRS415-cgb promoter-lacZ Ap This work 
E. coli MC1000  pSU2718-G-nssR Gm This work 
E. coli MC1000 pRS415 Ap This work 
E. coli MC1000  
pRS415-cgb promoter-lacZ 
pSU2718-G-nssR 
Ap, Gm This work 
E. coli D ? ? ? ?ȴǇĨŐ& pRS415-cgb promoter-lacZ Ap, Cm This work 
E. coli D ? ? ? ?ȴyfgF  pSU2718-G-nssR Cm, Gm This work 
E. coli D ? ? ? ?ȴǇĨŐ& pRS415 Ap,Cm This work 






Table 2.1.  Bacterial strains and plasmids used in this work. Working concentrations: Ap, 







Bacterial strains were streaked out on LB Agar plates supplemented with 
appropriate antibiotic at working concentrations displayed below table 2.1 and 
grown overnight in a 37oC incubator.  For preparation of starter cultures generally 1 
colony was inoculated in a sterile 50ml conical flask containing 10 ml of LB media 
supplemented with appropriate antibiotics as previously mentioned and then 
placed in a 37oC shaking water bath for growth overnight. 
2.1.2 Preparation of Growth Media 
2.1.2.1 Luria Bertani (LB) medium 
LB medium contained 10g tryptone, 5g yeast extract and 5g NaCl per litre.  pH was 
adjusted to 7.0 using NaOH then medium was autoclaved. 
2.1.2.2 Super optimal broth (SOB) 
To prepare SOB medium, 20g tryptone, 5g yeast extract, 0.584g NaCl and 0.186g 
KCl was added to 990ml of milli-Q water and autoclaved.  Once cooled to below 
60oC, 10ml of sterile 2M Mg2+ stock was added. To prepare the 2M Mg2+ stock, 
20.33g MgCl2 and 24.65 g MgSO4 were brought 100 ml with milli-Q water then filter 
sterilized with 0.2Pm filter. 
2.1.2.3 Super optimal broth with catabolite repression (SOC) 
To prepare SOB medium, 20g tryptone, 5g yeast extract, 0.584g NaCl and 0.186g 
KCl was added to 970ml of milli-Q water and autoclaved.  Once cooled to below 
60oC, 10ml of sterile 2M Mg2+ stock and 20ml of 1M glucose stock was added. To 
prepare the 2M Mg2+ stock, 20.33g MgCl2 and 24.65 g MgSO4 were brought 100 ml 
with milli-Q water then filter sterilized with 0.2Pm filter. 
2.1.2.4 2X YT media 
 To 900ml distilled H20 the following was added.  16g Bactotryptone, 10g yeast 
extract, 5g NaCl.  pH was then adjusted to 7 10M NaOH and then distilled H2O was 




2.2 Genetic methods 
 
2.2.1 Isolation of plasmid DNA 
A single colonies of E. coli strains harbouring plasmid required were picked to 
inoculate 10ml of LB supplemented with appropriate antibiotics of their respective 
antibiotic resistances to working concentration as illustrated in table 1 and incubated 
overnight at 37o C and 180rpm.  Plasmids were miniprepped following QIAprep Spin 
Miniprep Kit (from QIAGEN) protocol using a microcentrifuge with 4ml of each 
overnight culture. 
 
2.2.2 Confirmation of plasmid integrity 
 
Plasmid lengths were confirmed by linearizing the plasmids by restriction digestion. 
For a single digest (20 µl volume): 
In a 1.5 ml eppendorf tube the follwing were added, 2 µL 10X appropriate enzyme 
buffer, 1.5 µL appropriate restriction enzyme and purified plasmid DNA.  Generally 
3µL of plasmid was used but the volume will depend on the concentration of your 
DNA.  H2O was then added to bring the final volume up to 20 µl. 
For a double digest (20 µl volume):  In a 1.5 ml eppendorf tube the follwing were 
added, 2 µL 10X appropriate enzyme buffer, 1.5 µL restriction enzyme 1, 1.5 µL 
restriction enzyme 2 and purified plasmid DNA.  Generally 3µL of plasmid was used 
but the volume will depend on the concentration of your DNA.  H2O was then 
added to bring the final volume up to 20 µl. 
Incubation times and temperatures varied for use with different restriction 



































































Amplification of cgb promoter 
fragment for cloning into pSB1C3 








Amplification of cgb promoter 
fragment for cloning into pSB1C3 
backbone for IV transcription 
Reverse 
 
Table 2.2.  Oligonucleotides used in this work. Oligonucleotides were designed and then 
checked using the primer design feature of sequence analysis and design software Vector 
NTI to ensure that G/C content of primer was appropriate.  Oligonucleotides were 








2.2.4 Agarose gel electrophoresis 
 
Electrophoresis was performed in a gel apparatus at a constant voltage of 150v in 
1X TAE buffer (40mM Tris-acetate and 1mM NaEDTA).  Gels were generally 
composed of 1% agarose dissolved in 1X TAE, however if fragments were expected 
to be below 0.5kb a 2% agarose gel was used.  1µL of 6X Blue/Orange load dye 
(Promega) was mixed with 5µL of sample before loading in gel wells.  A 1kb or 
100bp ladder (NEB) was resolved on each gel to determine the size of fragment 
samples.  Gel were stained in ethidium bromide diluted in water 1:20000 dilution 
(5µL in 100ml) rocking for 30 minutes before visualising bands on a Syngene G:BOX 
gel dock. 
 
2.2.5 Preparation of chemically competent cells 
 
100ml of sterile LB with appropriate antibiotics for was inoculated with 1mL of 
overnight culture in a 250mL sterile flask and incubated at 37 oC and 200 rpm until 
an OD600 of 0.4-0.5.  When the correct OD600 was reached, cultures were incubated 
on ice for 10 min prior to being harvested by centrifugation at 3000 rpm and 4 oC for 
8 min in falcon tubes.  The supernatant was then removed and remaining pellet was 
resuspended in 25mL of ice cold CaCl2 prior to being incubated on ice for a further 10 
min.  The cells were then harvested again under the same conditions then the pellet 
resuspended in 2mL of 100mM ice-cold CaCl2 and 2ml of 30% (v/v) glycerol and 
ĂůŝƋƵŽƚĞĚ ? ? ?ʅ>ƉĞƌƉpendorf tube prior to storage at -80oC.  
 
2.2.6 Transformation of E. coli strains 
 
50-100ng of plasmid DNA was added to 100 µl competent cells mixed gently by 
tapping on the tubes and then incubating on ice for 1h.   Cells were then heat shocked 
at 42 °C for 2 min before being placed back on ice for a further 15 min.   1ml of LB 
was added to the cells and then incubated at 37 °C, shaking at 200 rpm for a further 
1 h.  Cells were then harvested by centrifugation at 5000 rpm for 5 min. 1mL of the 
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supernatant was gently removed and pellet was resuspended in 100 µl LB that 
remained in the tube.  The resultant culture was then plated onto agar plates with 
appropriate antibiotics then incubated at 37 °C overnight. 
 
2.2.7 Preparation of electro-competent cells  
 
50 ml SOB was inoculated in a 250 ml flask with 1mL of overnight culture (LB) and 
then grown at 37°C and 180rpm to an OD600 of approximately 0.4-0.8.  Cells were 
then kept on ice from this point on and transferred to two 50 ml sterile Falcon tubes.  
The culture was then centrifuged for 10 min at 4°C (3000 x g) and the pellet was 
resuspended in 5 ml ice-cold 10% glycerol by gently pipetting up and down.  The 
centrifugation and washing with 10% glycerol was repeated three times.  The cells 
were then centrifuged and the pellet was resuspended in 200 Pl 10% glycerol and 
transferred to a cold 1.5 ml eppendorf tube and kept on ice. 
 
2.2.8 Electroporation of plasmid DNA 
 
500-1000ng of purified plasmid or water for the control were added to the side of a 
sterile electro-cuvette on ice.   40 µl of electro competent cells were then added to 
the electro-cuvette and electroporated using the following settings: Voltage (V) 
2450V, CapacitaŶĐĞ ? ?A?& ?ZĞƐŝƐƚĂŶĐĞ ? ? ?ɐĂŶĚƵǀĞƚƚĞ ?ŵŵ. 1 ml of SOC was then 
added to the electro-cuvette and culture was transferred to a new sterile 1.5mL 
Eppendorf tube before being subjected to gentle agitation for approximately 1 hour 
at 37°C.   The culture was then centrifuged for 5 min at 5000 rpm and 940 µL of the 
resulting supernatant was removed.  The pellet was then resuspended gently in the 
remaining 100 ʅ>ŽĨĐƵůƚƵƌĞƚŚĞŶƉůĂƚĞĚŽŶƚŽĂ>ĂŐĂƌƉůĂƚĞǁŝƚŚĂŶƚŝďŝŽƚŝĐƌĞƐŝƐƚĂŶĐĞ






2.2.9 Screening transformants via colony PCR 
 
Individual colonies from transformation plates were patched onto new plates with 
appropriate antibiotics. Antibiotics were at at working concentrations indicated in 
Table 2.1. From these patched plates Colony PCR was carried out to confirm the 
identity of plasmids by performing PCR with plasmid-specific primers and then 
resolving the fragments via agarose gel (1 % TAE) electrophoresis.   
The cell suspension was prepared by suspending ĂƐŝŶŐůĞĐŽůŽŶǇŝŶƚŽ ? ?ʅ>ŽĨƐƚĞƌŝůĞ
water in an Eppendorf tube. In sterile PCR tubes, the following solutions were added: 
9.5uL sterile water, 0.5uL forward primer from 10 µM stock, 0.5µL reverse primer 
from 10µM stock , 2µL of cell suspension and 12.5uL 2x PCRBIO Taq Mix Red (primers 
used for pRS415, pRS415-cgb and pRS415-ctb plasmids were pRS415-seqF and 
pRS415-seqR and for pSU2718-G-nssR plasmid primers pSU2718nssR_seqF  
pSU2718nssR_seqR). The following programme was then ran on the PCR machine: 
 
95°C for 4 min 
95°C for 15 s 
57°C for 15 s      - 35 cycles 
72°C for 30 s 
72°C cycle for 2 min 
PCR products were analysed on a 1% (v/v) agarose gel (Section 2.2.4). 
2.2.10 cloning of cgb promoter 
 ? ? ?ďƉĨƌĂŐŵĞŶƚŽĨ ‘ƉZ^ ? ? ?-cgb ƉƌŽŵŽƚĞƌ ? ?Appendix A2) containing the cgb 
promoter and a portion of the lacZ gene was cloned via standard PCR using Q5 high 
fidelity polymerase from NEB (2X master mix) and the primers given in Table 2.2.  
The generated insert was purified using QIAquick PCR purification kit (QIAGEN) 
following their provided protocol.  As the psB1C3 backbone already had an insert 
(Appendix A4) the plasmid had to be digested by restriction enzymes EcoRI and PstI 
as described in (2.2.2) and resultant desired backbone fragment had to be purified 
by gel extraction from a 1% gel as described in (2.2.4).  QIAquick Gel extraction kit 
(from QIAGEN) protocol was followed using a micro centrifuge to isolated the 
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anticipated fragment.  DNA concentrations of insert and backbone were quantified 
using a NanoDrop to determine required quantities for ligation.   The cgb promoter 
fragment was then ligated into the EcoRI/PstI sites of the pSB1C3 vector upstream 
of the rrnB terminator (Figure 3.10A).     Ligations were performing using T4 DNA 
ligase from promega following their protocol and then where transformed into 
chemically competent TOP 10 cells prepared as indicated in section 2.2.5 to 
complete the ligation reaction.  Plasmid was then checked by restriction digestion 
using EcoRI/ PstI as described earlier. 
2.2.11 IV transcription experiment 
In a 20µL reaction 5µM NssR was incubated with 8nM pSB1C3-cgb promoter 
plasmid, 0.5mM of each ribonucleotide (4µL of a ribonucleotide solution mix from 
NEB containing 25mM of each nucleotide), 50µM of each cAMP, cGMP and c-di-
GMP and 1X reaction buffer provided with the RNA polymerase.  After a 20 minute 
pre-incubation at 37oC, 2 units of RNA polymerase holoenzyme from NEB saturated 
in sigma factor 70 was added and a further incubation of 20 minutes at 37oC was 
carried out.  To stop the reaction 60µL of Ambion NorthernMax formaldehyde Load 
Dye was added and then incubated for 15 minutes at 65oC to denature any 
secondary RNA structures.  40µL of this sample was loaded onto a 5.5% TBE gel run 
at 150V and resultant gel was visualised with Sybr green II RNA stain. 
 
2.3 Biochemical methods 
 
2.3.1 Purification of NssR 
2.3.1.1 Protein expression 
A 10ml Starter culture of BL21 strain containing the pGEX-kG-nssR plasmid were 
transferred into 2L baffled flasks containing 1L of 2X YT growth media 
ƐƵƉƉůĞŵĞŶƚĞĚǁŝƚŚŵƉŝĐŝůůŝŶ ? ? ? ?ʅŐ ?ŵů )ƵŶĚĞƌƐƚĞƌŝůĞĐŽŶĚŝƚŝŽŶƐ.  The culture was 
then grown in shaker at 30oC at 200 rpm until an OD of 0.4-0.5 had been reached.  
When the correct OD of the cultures had been reached IPTG was added to a final 
concentration of 0.4mM to induce overexpression of NssR.  The cultures were then 
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incubated for a further 5 hours.  After 5 hours the cells were then harvested by 
centrifugation at 6000Rpm for 20 min and 4oc.  The resulting pellets were frozen at 
-20oC in preparation for future purification. 
 
2.3.1.2 Purification with GSTrap column 
A pellet from 1L culture was resuspended in 30 ml cold PBS pH 7.3 (140mM NaCl, 
2.7mM KCl, 10mM Na2HPO4, 1.8mM KH2PO4) and then sonicated on ice for 6x30 
seconds at an amplitude of 10 microns to release the overexpressed protein from 
the cell.  Between each 30 second burst, sonication was stopped for 30 seconds to 
prevent heat damage of protein.  A 20µL sample was taken for an SDS PAGE gel 
labelled as Sn.  To remove cell debris the sonicated sample was then centrifuged at 
15000rpm for 20 minutes at 4oc and then kept on ice.  In preparation for 
purification by affinity chromatography a 5ml GSTrap column from GE lifecare was 
equilibrated with 5 column volumes of PBS at flow rate 1.5ml/min using a peristaltic 
pump.  After the column was equilibrated the Sn was applied and a sample of the 
flow was taken for SDS page (labelled FT), the column was then washed with 100 ml 
of PBS to remove any protein or debris not bound to GST beads.  
To elute the protein from the column 20 units of thrombin were added to 5ml PBS 
applied to the column flow stopped and left overnight to fully digest the GST tag.  
NssR was then eluted with 15ml of PBS into 1ml aliquots.  Location of protein in 
these aliquots was determined using the Bradford reagent.  If it was necessary to 
keep the GST tag intact when eluting NssR rather than thrombin 15ml of 10mM 







2.3.1.3 Heparin column removal of bound nucleotide 
Sample was buffer exchanged using a 10Kda vivaspin concentrator then diluting out 
with Heparin equilibration buffer (50mM NaH2PO4 pH 7.0).  5ml Heparin column 
from GE lifecare was equilibrated with 10 column volumes of the phosphate buffer 
at 1-5ml/min using peristaltic pump.  The sample was then applied and column 
washed with 5-10 column volumes of phosphate buffer.  The initial 10ml of this 
flow through was caught in 1ml aliquots and put aside for later spectral analysis to 
identify location of eluted bound substance.  The unbound NssR was then eluted 
with 10ml of high salt buffer (50mM NaH2PO4, 1M NaCl pH 7.0) a 20µL sample was 
taken for SDS PAGE labelled Heparin elution.  
2.3.2 SDS PAGE 
SDS PAGE was used to confirm purity of NssR at the various stages of purification as 
described in 2.3.1.  A 4% stacking gel was cast on top of a 15% resolving gels (once 
the resolving gel had set for approximately 45- 60 minutes.  Samples were prepared 
by adding loading dye in a 1:1 ratio.  Loading dye used had the following 
composition, 50mM Tris, 2 % SDS, 0.1 % Bromophenol blue, 10 % Glycerol and 
100mM DTT which was added just before use at pH 6.8.   Gels were run at 150v in 
1X SDS running buffer (0.1% w/v SDS, 25mM Tris, 250mM glycine, pH 8.3) until the 
dye front was approximately 1cm from the bottom of the glass plate.  Gel were 
then stained in instant blue for 20  W 30 minutes with no distaining required.  The 









 Volumes requires (ml) 
Chemicals 15% 4% 
Acrylamide 40% 3.8ml 1ml 
H2O 3.5ml 6.3ml 
1.5M Tris pH 8.8 2.5ml - 
0.5M Tris pH 6.8 - 2.5ml 
10% SDS 0.1ml 0.1ml 
10% APS 0.1ml 0.1ml 
TEMED 0.004ml 0.01ml 
 
 Table 2.3 Recipes for 15% and 4% SDS PAGE gel.  *TEMED is added immediately before 
casting                                                                                           
 
2.3.3 Mass spectrometry identification of NssR bound ligand  
HPLC/MS analysis was performed using HPLC Agilent 1100 system coupled to 
micrOTOF-Q11 Mass spec from Bruker on negative electrospray mode. Separations 
occurred on Nucleosil 120A c18 column with 3µm (bead size) and dimension 
150mm x 2mm.  The protocol was adapted from (Van Damme 2012) in which cAMP 
and cGMP were identified from human plasma samples[36].  Flow rate was 
adjusted to 5ml/min from to compensate for using a 150mmx 2mm column rather 
than 150mm x 3mm.  Solvent A was 0.1% formic acid and solvent B 
acetonitrile/methanol/water in volume ratio 1/2/4. A linear gradient was used with 
initial conditions 100% A and increasing solvent B from 0% to 50% in 10 min. 
Solvent B then went to 100% B in 1 min to clean the column and maintained for 1 
min, followed by column regeneration for 10 min.  Sample injection size was 20µL 
and 3 replicates were carried out.  Rather than using negative-ion multiple reaction 
monitoring mode (MRM) which is time consuming and costly to set up a more 
generic fragmentation method was used.  25eV alternating between fragmented 
and intact and measured in the range of 50  W 1250m/z.  Negative electrospray was 
used with capillary voltage 2300v.  For identification of Cyclic nucleotides EIC 
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(extracted ion chromatograms) were used to look for qualified ions identified in the 
previously mentioned paper. 
 
2.3.4 Co-purification of NssR with cAMP and cGMP 
NssR was purified with GST tag still intact as described in 2.3.1.2 was then 
concentrated using 10kda viva spin concentrator and protein concentration 
identified using a NanoDrop.  To 10µM NssR, 500µM cAMP or cGMP were added 
incubated for 30 minutes the sample was then added to an equilibrated GST 
column, which was then washed then left overnight to digest with thrombin and 
then eluted the next day as described in purification protocol 2.3.1.  A control 
experiment was also carried out adding no substrate. 
2.3.5 Tryptophan fluorescence assay 
 
Fluorescence Titrations were performed in a Fluorimeter using 2ml of 0.2µM NssR 
protein unbound by nucleotide (diluted in 50mM NaH2PO4 pH 7.0) in a 2ml quartz 
fluorescence cuvette.  NssR stocks were made and quantified as described in 
section 2.3.1 and 1mM Stocks of cyclic nucleotides cAMP, cGMP and c-di-GMP were 
prepared for use in the titrations. The protein was scanned for fluorescence over a 
wavelength range of 310nm  W 400nm with an excitation wavelength of 295nm to 
avoid the shoulder of fluorescence readings of cyclic nucleotides as they absorb at 
around 260nm. The ligand of interest was then slowly titrated into the sample in 
fractions from 0.2µM to 10µM.  Between each titration the sample was gently 
mixed by pipetting up and down then left briefly to equilibrate (few seconds) 
before another scan being taken over the same wavelength range. Increasing 
concentrations of ligand was successively added in the same increments until there 
was no apparent change in fluorescence. The titration was then repeated using the 
same ligand stocks and the fluorescent compound N-acetyl-tryptophanamide 
(NATA) as a control reaction toaccount for any change in fluorescence caused by 
the added ligand. The NATA was added until the fluorescence at 360nm was 
roughly equal to that of the original protein before adding the same quantities of 




2.3.6 Electrophoretic mobility shift assay 
 
Colony PCR with primers designed to anneal to the T7 and SP6 sites on the pGEM-T 
vector (table 2.2.) was used to amplify a 171 bp fragment containing the cgb 
promoter NssR-binding site.  Target DNA (25 nM) and purified NssR were pre-
incubated in binding buffer (20mM Tris WHCl, pH 7.8, 1mM EDTA, 3% glycerol) for 30 
min at room temperature, in the presence and absence of 0.2mM c-di-GMP, cAMP 
and cGMP. The reaction mixtures were then re- solved on an 8% non-denaturing 
TBE polyacrylamide gel with a 4% stacking gel, and stained with ethidium bromide. 
Densitometry software (ImageJ) was used to quantify the relative abundance of 
NssR:DNA complex and un- bound target DNA. 
2.4 ɴ-galactosidase in vivo reporter system 
 
To prepare Z buffer, the following were added to a 500mL Duran bottle: 300ml of 
miliQ water, 60 mM Na2HPO4, 40 mM NaH2PO4, 10 mM KCl, 1mM MgSO4. This was 
then stirred with a magnetic stirrer and adjusted pH to 7.  The Duran bottle was then 
filled to 500 mL with milli-Q water and wrapped in foil to protect it from light and 
stored at 4oc. Cells were grown anaerobically overnight by inoculating 45 ml of LB in 
a 50 ml falcon tube with a single colony with and incubated at 110 rpm and 28oC.  
Immediately before experiments were conducted OD600 was measured. 
The following was the added to glass test tubes and then vortex mixed thoroughly: 
 ? ? ?ʅ>ďƵĨĨĞƌ ? ? ?ʅ>ŽĨ ? P ? ? ?ĚŝůƵtion of ĐƵůƚƵƌĞ ? ?ʅ>ŽĨ ? ? ?A?ĂŶĚ ? ?ʅů,ů ?dƵďĞƐ
were then incubated at 28oC for 5 min and then the reactions were started by adding 
100 ʅ> ŽĨ  ?ŵŐ ?ŵů KEW' ĚŝƐƐŽůǀĞĚ ŝŶ  ďƵĨĨĞƌ ?  tŚĞŶ Ă ƉĂůĞ ǇĞůůŽǁ ĐŽůŽƵƌ ŚĂĚ
developed reactions were stopped by adding 250 ʅ>ŽĨ ?DEĂ2CO3, making sure to 
take note of stop and start times for the assay.  The OD420 and OD550 of these samples 
was then measured then miller equation used to work out miller units of expression 
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CHAPTER 3 - RESULTS 
 
3.1 Structural modelling of NssR 
 
To further investigate the hypothesis that NssR can bind cyclic nucleotides, structural 
modelling was carried out.  The amino acid sequence of NssR was obtained from 
Uniprot and a structural model for NssR was generated using the online modelling 
program RaptorX [37].  RaptorX identifies protein crystal structures from the RCSB 
Protein Data Bank (PDB) that display structurally biased sequence homology to the 
input protein, and these templates are then used to model the desired structure. 
Table 3.1 shows the top 5 hits in rank order for proteins identified as suitable 
templates for structural modelling of NssR.  These proteins are predominantly CRP-
family transcriptional regulators that have been shown to bind cAMP, suggesting a 
potential role for cyclic nucleotide binding for the NssR mechanism.   
 
Model 

























Cyclic AMP receptor-like 
protein 2OZ6 cAMP 
 
Table 3.1 - PDB structures identified as suitable templates for NssR structural modelling.  
Model rank provides a measure of structural homology to NssR.  
The most homologous of these template structures, CRP-like protein from T. 
thermophilus (3.1A) was therefore used as a comparison to ascertain the likeliness 
of cyclic nucleotides binding to NssR in the molecular graphics program CCP4MG.   
CCP4MG was used to initially identify the possibility that NssR could accommodate 
binding of cyclic nucůĞŽƚŝĚĞƐ ?ĨŝŐƵƌĞ ? ? ? ) ?dŽĂĐŚŝĞǀĞƚŚŝƐ ?ɲĂƚŽŵƐĨŽƌƚĞŵƉůĂƚĞ
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and model were superimposed to model the cAMP ligand from the template into 
the binding cleft of the NssR model (Figure 3.1B).  This initial investigation 
suggested binding pocket of NssR was sufficiently large enough to accommodate 
cyclic nucleotide binding.  Subsequently CCP4MG was then used to identify whether 
important sidechains in the template (3.2A) were conserved in the modelled 
binding pocket of NssR (3.2B) 
 
 
Figure 3.1 - Structural modelling of NssR.  (A) Catabolite activator protein (PDB id = 4EV0). 
4EV0 was used as a template to generate this structural model of NssR (B). The cAMP of 4EV0 
is shown modelled into the binding cleft of each monomer of NssR shown in 3.1B. 
 
 
Figure 3.2B displays a view of the NssR model looking into the binding cleft along the 
plane of the adenine ring of cAMP, with adjacent amino acid sidechains highlighted. 
This analysis suggests that the binding pocket of NssR may provide a suitable 
environment for cyclic nucleotide binding as many of the side chains are conserved 




hydrophobic residues of binding pocket of Crp are conserved in NssR.  The majority 
of substitutions that have occurred are between side chains which have similar 
characteristics or size, for example Leucine 53 in Crp being substituted for Isoleucine 
43 in NssR Both are small hydrophobic residues with similar function.  There are 
however notable exceptions to this, the most significant being both Arginine residues 
of Crp (residue 85 and 126) have been substituted with Tyrosine 75 and Lysine 116 
respectively.  This is notable as arginine residues are frequently found in binding sites 
and are especially are proficient in binding the negatively charged groups on 
phosphates.  This is important for binding of cAMP as when it binds (shown in fig 3.1 
and 3.2) its phosphate residues are buried deep within the protein.  Lysine can also 
interact with phosphates in a similar way to arginine also being a positively charged 
residue however this interaction is more limited as it can form less H bonds with the 
negatively charged phosphate groups.  There are 3 additional binding residues 
predicted in NssR not in positions found in Crp.  These are glutamic acid, alanine and 
isoleucine.  Both isoleucine residues and alanine are fairly non consequential for 
binding however glutamic acid residues are frequently involved in binding due to 
their short rigid nature and negative charge.  These significant residue differences 
between the binding sites may result in cyclic nucleotides binding in a different 










Figure 3.2  ? Cyclic nucleotide-binding clefts of Crp and a NssR structural model. A) The 
cAMP-binding cleft of 4EV0 looking into nucleotide binding cleft along the plane of adenine 
ring of bound cAMP. B)  The cAMP-binding cleft of the NssR model looking into nucleotide 












3.2 - Purification of NssR 
 
NssR of C. jejuni was overexpressed and purified by affinity chromatography as 
described in Section 2.3.1.  To determine purity, SDS-PAGE was carried out as 
described in Section 2.3.2 Results from the resolved gels (example in figure 3.3) 
show that a protein corresponding to the predicted molecular weight of untagged 
NssR (approximately 23kDa) was present in the elution fraction fractions from the 




Figure 3.3 - Purification of NssR. NssR was purified via GST affinity chromatography 
followed by removal of bound nucleotides/DNA using a heparin column.  Lane 1  Protein 
Marker,  Lane 2 supernatant from pelleted sample, Lane 3 flow through from GSTrap 
column,  Lane 4 1st protein elution from GSTrap column, Lane 5 2nd elution from GSTrap 
column, Lane 6 flow through from Heparin column, Lane 7 eluted Heparin treated protein. 
 
Analysis of the purified NssR via UV/Vis spectroscopy in figure 3.4(A) shows that the 
purified protein has a sharp peak at 258nm typical of nucleotide.  This would 
suggest that the protein was purified with the nucleotide bound.  There is a clear 
observable shift to 280nm in fig 3.4 (B) after the protein has been treated in the 
heparin column as described in 2.3.1 confirming that the bound nucleotide has 
been removed and the protein is now unbound. 














Figure 3.4  ? UV-visible absorption spectroscopy of purified NssR. Absorption spectra for 
NssR eluted from the GST and heparin columns demonstrate that the heparin column 
removed bound nucleotides co-purified with NssR.  (A) (absorbance maximum = 260 nm) 
associated with nucleotide (B) (absorbance maximum = 280 nm) associated with protein 





3.3 Analysis of nucleotide co-purified with NssR via mass spectrometry 
 
In an attempt to identify the nucleotides that were co-purified with NssR (Section 
3.2), the heparin flow through fraction (Figure 3.3) was collected for further analysis 
via mass spectrometry.  This sample was confirmed to have the expected 
absorbance characteristics of a peak around 255-260nm characteristic of 
nucleotides (Figure 3.5). 
 





































Figure 3.5  ? UV-visible absorption spectroscopy of nucleotide that is co-purified with NssR. 




A HPLC/MS approach (Section 2.3.3) was undertaken in an attempt to identify the 
nucleotide that is co-purified with NssR. This approach is based upon a previously 
characterised technique that has been used to identify cGMP and cAMP from human 
blood plasma[36].  This work identified a species with a mass peak at 154.9 Da (Figure 
3.6), which could potentially be a protonated guanine base, possibly resulting from 
the fragmentation of c-di-GMP during the mass spectrometry process.  Other notable 
peaks at 112.9 and 248.9 are due to sodium trifluoracetate that was in solvent A 
(0.1% formic acid).   



















Figure 3.6  ? HPLC/Mass spectrometry analysis of nucleotide that is co-purified with NssR.  
HPLC/MS analysis was performed on the heparin flow through fraction (Figure 3.3).  Figure 
shows mass peaks from an extracted ion chromatogram at 150m/z looking for qualifier 
daughter ions found in Van damme 2012 paper.   
 
3.4. Co-purification of cAMP and cGMP with NssR 
 
To demonstrate that NssR can directly bind cyclic nucleotides, purified unbound GST-
tagged NssR was isolated via GST affinity chromatography and eluted with reduced 
glutathione. Bound nucleotide was then removed via using a heparin column. Tagged 
NssR (10 µM) was then mixed with cAMP (500 µM) or cGMP (500 µM), followed by 
GST affinity chromatography and elution via cleavage of the GST tag with thrombin 
(Section 2.3.1).  A negative control experiment was performed with NssR alone, but 
an experiment was not conducted with c-di-GMP due to the costly nature of the 
nucleotide.  If nucleotide was bound to the eluted fraction, a shift in absorption 
maximum from 280 nm (protein) to 260 nm (nucleotides) would be expected.  
Absorption spectra of eluted fractions from this experiment (Figure 3.7) clearly show 









Figure 3.7  ? Absorption spectra of NssR bound to cyclic nucleotides. NssR was preincubated 
for 20 min in the presence of cAMP or cGMP, bound to a GST affinity column and washed, 
and then eluted via cleavage of the GST tag with thrombin. Absorption spectra show that 
eluted NssR was bound to cAMP (red trace) or cGMP (green trace). A control experiment was 
also performed without nucleotide (blue trace). 
 
3.5. Measurement of binding affinities of NssR for cyclic nucleotides 
To gain an insight into the relative affinity of NssR for various cyclic nucleotides, 
ƚƌǇƉƚŽƉŚĂŶĨůƵŽƌĞƐĐĞŶĐĞƋƵĞŶĐŚŝŶŐƚŝƚƌĂƚŝŽŶƐǁĞƌĞ ƉĞƌĨŽƌŵĞĚ  ?^ĞĐƚŝŽŶ  ? ? ? ? ? ) ?dŚŝƐ
ƚĞĐŚŶŝƋƵĞĞǆƉůŽŝƚƐĐŚĂŶŐĞƐŝŶĨůƵŽƌĞƐĐĞŶĐĞǇŝĞůĚŽĨƉƌŽƚĞŝŶƚƌǇƉƚŽƉŚĂŶƌĞƐŝĚƵĞƐƚŚĂƚ
ƌĞƐƵůƚ ĨƌŽŵ ĐŽŶĨŽƌŵĂƚŝŽŶĂů ĐŚĂŶŐĞƐ ƵƉŽŶ ůŝŐĂŶĚ ďŝŶĚŝŶŐ ? EƐƐZ ŚĂƐ Ă ƐŝŶŐůĞ
ƚƌǇƉƚŽƉŚĂŶ ƌĞƐŝĚƵĞ Ăƚ ƉŽƐŝƚŝŽŶ  ? ? ? ? ƐŽ ŝƚ ǁĂƐ ĚĞĐŝĚĞĚ ƚŚĂƚ ƚŚŝƐ ǁĂƐ Ă ƐĞŶƐŝďůĞ
ĂƉƉƌŽĂĐŚƚŽĂŶĂůǇƐĞůŝŐĂŶĚďŝŶĚŝŶŐ ?/ŶďƌŝĞĨ ?EƐƐZ ? ? ? ?A?D )ǁĂƐĞǆĐŝƚĞĚĂƚ ? ? ?Ŷŵ
ĂŶĚĨůƵŽƌĞƐĐĞŶĐĞĞŵŝƐƐŝŽŶƐĐĂŶƐǁĞƌĞƌĞĐŽƌĚĞĚ ?ƉƉĞŶĚŝǆ ? )ĨŽůůŽǁŝŶŐƚŝƚƌĂƚŝŽŶŽĨ
ƚŚŝƐ ƐŽůƵƚŝŽŶ ǁŝƚŚ ƐŵĂůů ǀŽůƵŵĞƐ ŽĨĐDW ? Đ'DW ?ĂŶĚ Đ ?Ěŝ 'DW ?ŽŶƚƌŽů ƚŝƚƌĂƚŝŽŶƐ
ǁĞƌĞĂůƐŽƉĞƌĨŽƌŵĞĚƵƐŝŶŐƚŚĞĨůƵŽƌĞƐĐĞŶƚƐŵĂůůŵŽůĞĐƵůĞE ?ĂĐĞƚǇůƚƌǇƉƚŽƉŚĂŶĂŵŝĚĞ
 ?Ed )ŝŶƉůĂĐĞŽĨEƐƐZ ?ǁŚŝĐŚƉƌŽǀŝĚĞĂŵĞĂƐƵƌĞŽĨƐŝŐŶĂůĐŚĂŶŐĞƐƚŚĂƚĐĂŶƌĞƐƵůƚ
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ĨƌŽŵƚŚĞŽƉƚŝĐĂůƉƌŽƉĞƌƚŝĞƐŽĨƚŚĞůŝŐĂŶĚ ?dŚĞĨůƵŽƌĞƐĐĞŶĐĞŵĂǆŝŵĂĂƚ ? ? ?ŶŵǁĞƌĞ
ƉůŽƚƚĞĚ ĂŐĂŝŶƐƚ ůŝŐĂŶĚ ĐŽŶĐĞŶƚƌĂƚŝŽŶ ? ĂŶĚ ďŝŶĚŝŶŐ ĐƵƌǀĞƐ ǁĞƌĞ ĨŝƚƚĞĚ ƚŽ ƐŝŶŐůĞ
ƌĞĐƚĂŶŐƵůĂƌŚǇƉĞƌďŽůĂĞǀŝĂŶŽŶůŝŶĞĂƌƌĞŐƌĞƐƐŝŽŶƵƐŝŶŐ^ŝŐŵĂƉůŽƚ ?&ŝŐƵƌĞ ? ? ? ) ?dŚĞƐĞ
ĚĂƚĂƌĞǀĞĂůĚŝƐƐŽĐŝĂƚŝŽŶĐŽŶƐƚĂŶƚƐŽĨ ? ? ?A?D ? ? ? ?A?D ?ĂŶĚ ? ? ?A?DĨŽƌĐDW ?Đ'DW ?




Figure 3.8 - Tryptophan 
fluorescence quenching 
titrations of NssR with 
cyclic nucleotides.  To a 
fixed concentration of 
0.2µM NssR, cAMP, cGMP, 
and c-di-GMP were titrated 
over a concentration range 
of 0.2µM to 10µM.  
Samples were excited at 
295nm and fluorescence 
emission scans were 
recorded from 300-400nm 
at 200nm/min. The 
fluorimeter had excitation 
slits set to 5 nm and the 
emission slits were set to 
10 nm.  To determine 
whether the ligand 
absorbance directly 
affected fluorescence 
values control titrations 
were carried out for each 





3.6 - Electrophoretic mobility shift assay to investigate how cyclic 
nucleotides effect NssR affinity for the cgb promoter 
 
After confirming that cAMP, cGMP, and c-di-GMP can bind to NssR, it was of interest 
to determine whether these ligands affect NssR binding to the target promoter. Gel 
shift assays were carried out essentially as described previously[25]. Briefly, a DNA 
fragment containing the cgb promoter was amplified via PCR and 25 nM of this was 
incubated with various concentrations of NssR in the presence of cAMP, cGMP, and 
c-di-GMP. To measure the fraction of DNA that was bound to NssR, electrophoretic 
mobility shift assays were perfomed (Section 2.3.6): binding of NssR to the cgb 
promoter was expected to slow migration of the DNA resulting in a band shift.    
These data in figure 3.9 demonstrate that binding of c-di-GMP to NssR increases 
affinity for the cgb promoter (3.9B) whereas cAMP and cGMP (3.9C and 3.9D 
respectively) appear to cause a decrease in affinity with complete inhibition of 
binding in the case of c-GMP.  There is substantial binding of NssR to the promoter 
















Figure 3.9  ? Gel Shift analysis of NssR binding to the cgb promoter in the presence of cyclic 
nucleotides.  Target DNA (25 nM) was incubated with varying concentrations of NssR in the 
absence (panel A) and presence of 0.2mM c-di-GMP (B), cAMP (C) and cGMP (D). Panel E 
shows intensities of the gel bands at increasing concentrations of NssR in the absence of 
presence of the cyclic nucleotides (0.2mM) 
- Cyclic nucleotide + 0.2mM c- -  




































































































































3.7  ? Attempts to measure NssR activity via in vitro transcription assays 
Since the gel shift assays suggested that the affinity of NssR for the cgb promoter was 
still at significant levels when not in the presence of c-di-GMP, it was hypothesised 
that NssR binds permanently to the target promoter and nucleotide binding causes 
a conformational shift to promote transcriptional activation. In an attempt to 
measure transcriptional activation by cyclic nucleotide, in vitro transcription studies 
were carried out (Section 2.2.11) following the generation of a suitable target DNA 
fragment. 
 3.7.1 Construction of template DNA for in vitro transcription 
In vitro transcription assays involve the production of mRNA from a target DNA 
template of a convenient size that is upstream of a strong transcriptional terminator. 
This target DNA template was engineered via amplification of a 364 bp fragment of 
 ‘pRS415-cgb promoter ? (Appendix A2) containing the cgb promoter and a portion of 
the lacZ gene (Section 2.2.10). This was then cloned into the EcoRI/PstI sites of the 
pSB1C3 vector upstream of the rrnB terminator (Figure 3.10A). 
 
 
Figure 3.10  ? Generation of a DNA template for in vitro transcription. A) Map of the desired 
 ‘Ɖ^ ? ?-cgb ƉƌŽŵŽƚĞƌ ?vector containing the cgb promoter and a portion of the lacZ gene. 
B) Agarose gel electrophoresis of restriction-ĚŝŐĞƐƚĞĚ ‘Ɖ^ ? ?-cgb ƉƌŽŵŽƚĞƌ ?ƉůĂƐŵŝĚ. Lane 
1, marker; Lane 2, EcoRI single digest; EcoRI/PstI double digest. Expected fragment sizes for 














3.7.2 In vitro transcription assays to measure NssR activity 
In an attempt to measure the effect of cyclic nucleotides upon NssR activity, in vitro 
transcription assays were performed (Section 2.2.11) using  ‘Ɖ^ ? ?-cgb ƉƌŽŵŽƚĞƌ ? 
as a template and c-di-GMP as the nucleotide. Transcriptional activity would result in 
the amplification of mRNA of approximately 500 bases in length. Attempts to amplify 
mRNA in the presence and absence of NssR were unsuccessful (Figure 3.11), and 
unfortunately the lanes in the nondenaturing gel electrophoresis did not migrate 
vertically.  
 
3.8. In vivo B-galactosidase reporter system to measure the impact of c-di-
GMP upon NssR activity 
 
Since the in vitro transcription approach was unsuccessful (Section 3.7), an in vivo 
approach (Section 2.4) was employed to investigate the effect of c-di-GMP upon NssR 
activity. Briefly, a yfgF strain of E. coli, lacking a c-di-GMP phosphodiesterase and 
therefore retaining higher levels of c-di-GMP, was used alongside the isogenic wild 
type strain. These strains were transformed with both an NssR expression plasmid 
(PSU2718-G-nssR Appendix A3) and a reporter plasmid with the cgb promoter 
upstream of the lacZ gene encoding ɴ Wgalactosidase (Appendix A2). Briefly, cells 
were grown to stationary phase at 110 rpm as expression of yfgF has previously been 
shown to require low oxygen conditions, and NssR expression was induced with IPTG. 
Figure 3.11  ? Nondenaturing PAGE of in 
vitro transcription assays. Lane 1, RNA 
marker lane 2; negative control (+c-di-
GMP, - NssR); Lane 3 test, (+c-di-GMP, - 
NssR). Template DNA is highlighted by the 
red boxes, and no mRNA product could be 
detected. 
1 2 3 
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Transcriptional activity from the cgb ƉƌŽŵŽƚĞƌ ǁĂƐ ŵĞĂƐƵƌĞĚ ǀŝĂ ɴ Wgalactosidase 
assays (Section 2.4), and the data (Figure 3.13) show that the loss of yfgF and 
consequent increase in cellular c-di-GMP elevates transcription initiation at the cgb 
promoter only when NssR is expressed. This observation indicates that c-di-GMP is a 




Figure 3.12. NssR activity is enhanced by cyclic-di-GMP.  Wild type (blue bars) and yfgF 
ŵƵƚĂŶƚ ƐƚƌĂŝŶƐ  ?ƌĞĚ ďĂƌƐ ) ǁĞƌĞ ƚƌĂŶƐĨŽƌŵĞĚ ǁŝƚŚ  ‘Ɖ^h ? ? ? ?-G-ŶƐƐZ ? ĂŶĚ  ‘pRS415-cgb 
ƉƌŽŵŽƚĞƌ ? PƐƚƌĂŝŶƐĐŽŶƚĂŝŶŝŶŐƚŚĞƐĞƉůĂƐŵŝĚƐĂƌĞĂŶŶŽƚĂƚĞĚĂƐŐďĂŶĚEƐƐZ ?ƌĞƐƉĞĐƚŝǀĞůǇ ? 
All strains grown at 28 oC and 110 rpm to stationary phase in LB with appropriate antibiotics.  
Expression of NssR was induced with IPTG. Transcriptional activity of the cgb promoter was 
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CHAPTER 4 - DISCUSSION 
 
NssR is a transcriptional regulator of C. jejuni shown to have function in NO 
detoxification through control of a small regulon containing globins Cgb and Ctb [26].  
The molecular mechanism for how NssR senses NO has remained elusive and 
previous studies have shown NssR not to be directly modulated by Nitric oxide [25].  
NssR does not possess any NO-binding cofactors (e.g. haem or iron-sulphur clusters) 
but has previously been identified as a member of the CRP family of transcription 
factors which commonly bind cyclic nucleotides. Phosphodiesterase and diguanylase 
cyclase enzymes, which control c-di-GMP levels, have previously been shown to be 
modulated by NO [34,35]. Hence, c-di-GMP is a strong candidate for being a second 
messenger in NO-mediated activation of NssR activity. This lead to the hypothesis 
that iŶĐƌĞĂƐĞĚ ůĞǀĞůƐ ŽĨ ĐǇĐůŝĐ Ěŝ ?'DW ǁŝůů ĞůĞǀĂƚĞ EƐƐZ ĂĐƚŝǀŝƚǇ ŝŶĐƌĞĂƐŝŶŐ Őď
ĞǆƉƌĞƐƐŝŽŶ ?&ŝŐƵƌĞ ? ? ? ) ? 
Structural modelling using the online RaptorX program in this work is 
consistent with NssR having a binding cleft that can accommodate cyclic nucleotides.  
Analysis of the surface of the NssR model shows a large binding pocket, large enough 
to accommodate cGMP or cAMP.  However, the binding of cAMP requires the 
phosphate end of cAMP to be buried deep within the protein with the adenine ring 
exposed.  This might pose a problem for c-di-GMP binding as the two GMP moieties 
are linked by the phosphates, so c-di-GMP would have to bind in an alternative 
orientation to the modelled cAMP in Figure 3.1.  However analysis of side chain 
binding of NssR carried out in this work has revealed the substitution of both Arginine 
residues found in Crp, which are heavily associated with the binding of negative 
phosphate residues by formation of multiple hydrogen bonds[38].  This would 
suggest that an alternative binding orientation for c-di-GMP would be highly likely.  
Additionally recent research on CRP family transcription factors has reported that 
members of this family that can bind both c-di-GMP, which fits well with the 
observations in the current study[39].   
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The co-purification of NssR with cAMP and cGMP provides robust biochemical 
evidence that NssR can bind cyclic nucleotides. This experiment was not performed 
with c-di-GMP due to cost issues, but it is anticipated that a similar result would be 
obtained.  The tryptophan fluorescence experiments are consistent with NssR being 
able to bind all three cyclic nucleotides in vitro, with tighter binding observed for c-
di-GMP and cAMP. 
As NssR has previously been shown to bind to the cgb promoter fairly tightly 
when not in the presence of a ligand it was initially predicted that binding of cyclic 
nucleotides would not increase affinity for the promoter but induce a conformational 
change to the protein leading to increased transcriptional activation [25], Gel shift 
assays carried out in this work show that c-di-GMP does in fact increases NssR affinity 
for the cgb promoter and lead to the possibility of both scenarios being true. 
To test the activity of NssR, in vitro transcription experiments were 
undertaken to directly measure mRNA transcript levels from a cgb promoter (Figure 
3.12). Unfortunately, these experiments were unsuccessful, possible due to 
detection levels using the gel staining method. More sensitive methods for detecting 
mRNA transcript levels are available, such as 35P-labelling of mRNA and 
autoradiograph detection. This may provide a sensible future strategy for measuring 
NssR activity in vitro. The in vivo approaches were more successful (Figure 3.13). The 
wild type and mutant strains lacking plasmids exhibited low leǀĞůƐŽĨɴ-galactosidase 
activity, which was expected as these strains do not possess the lacZ fusion and the 
MC1000 background strain lacks the chromosomal lac operon.  However, in all strains 
that contain the cgb-lacZ reporter plasmid, there is a fairly high residual level of LacZ 
expression, presumably due to leaky expression by the E. coli transcriptional 
machinery or via activation by an E. coli transcription factor. Expression in the 
absence of NO could be due to differences in how E. coli and C. jejuni respond to NO: 
this seems likely as C. jejuni lacks the NsrR transcription factor of E. coli that controls 
the major transcriptional responses to NO, and E. coli lacks NssR. Nonetheless, 
despite this high background signal, this remains a useful tool to investigate NssR 
activity in vivo. In the mutant strains harbouring the cgb-lacZ reporter plasmid, LacZ 
expression is not significantly increased when compared to wild type strains with cgb.   
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There is a slight increasĞŝŶ ůĞǀĞůƐŽĨɴ-galactosidase activity between WT Cgb and 
ȴyfgF Cgb strains, although this difference is not significant at the 95% level (t-test).  
Expression in WT CŐď ĂŶĚ ȴyfgF Cgb is still at a basal level in the absence of the 
transcriptional regulator NssR.   However, upon introduction of the NssR expression 
plasmid, the ȴǇĨŐ& Őď ŶƐƐZ ƐƚƌĂŝŶ ĚŝƐƉůĂǇĞĚ ƐŝŐŶŝĨŝĐĂŶƚůǇ ŝŶĐƌĞĂƐĞĚ ĞǆƉƌĞƐƐŝŽŶ
ĐŽŵƉĂƌĞĚƚŽƚŚĞȴǇĨŐ&ŐďĐŽŶƚƌŽůƐƚƌĂŝŶ, suggesting that cyclic-di GMP is enhancing 
NssR activity. 
 Herein, it is shown that c-di-GMP enhances NssR-mediated transcriptional 
activation of the cgb promoter.  However, it is still unclear how NO modulates c-di-
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Fig 4.1 Model for NssR mechanism in Campylobacter jejuni.  There are 2 possible routes via 
which NO may increase cyclic-di-GMP levels.  Route 1: NO is positively regulating diguanylate 
cyclase.  Route 2: NO is negatively regulating C-di-GMP phosphodiesterase activity.  
 
In conclusion, this work shows that c-di-GMP elevates NssR activity, which is likely 
to be the molecular signal that controls NssR activity in C. jejuni.  In essence, this 
work provides important insights into the molecular mechanism of NssR and 
provides a robust model for how C. jejuni senses and responds to NO in vivo. This 
has important implications for how C. jejuni survives nitrosative stress during 
infection, and provides a molecular explanation for how this zoonotic pathogen can 
persist in the avian gut. 
Future work in this area might include development of the in vitro transcription 
assays via radiolabelling of the mRNA for increased sensitivity, deletion of cyclase 
and phosphodiesterase genes in the native host followed by physiological 
experiments on NO tolerance, and determination of the crystal structure of NssR 






Figure A1  ? Fluorescence emission scans of NssR titrated with c-di-GMP 
 
 
Figure A2  ? The pRS415-cgb promoter plasmid. This was used to amplify target DNA for 





Figure A3  ? Map of the pSU2718-G-NssR plasmid used to express NssR in E. coli. 
This plasmid was used in the in vivo NssR reporter assay experiments. 
Figure A4- Map of the pSB1C3 BBa plasmid.  The BBa promoter was removed and 
this plasmid was used as the backbone to insert the cgb promoter fragment for IV 
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